PMID 14966297
Our talented and experienced medical professionals are skilled in providing a wide range of IV therapies and treatments to you in the comfort and privacy of your own place whilst always ensuring your optimum health and wellness
17 , e10079 (2021)
We are located at 1003 Division Street, Suite 4, Prescott, AZ 86301
How the study was designed Included adults 18 to 65 with type 2 diabetes who were newly prescribed one of three drug types: a GLP-1 receptor agonist (161,489 people), an SGLT-2 inhibitor (122,114 people), or a DPP-4 inhibitor (86,047 people)
Pfizer enters the fray, advancing an oral GLP-1 agonist, danuglipron, into phase 2 trials, aiming to innovate with a once-a-day oral diabetes treatment (Pfizer, 2023)